11-dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice

Endocrinology

Volumn 154, Issue 10, 2013, Pages 3599-3609

  Harno, Erika ^a   Cottrell, Elizabeth C ^b   Keevil, Brian G ^b,c   DeSchoolmeester, Joanne ^d   Bohlooly Y, Mohammad ^e   Andersén, Harriet ^e   Turnbull, Andrew V ^d   Leighton, Brendan ^d   White, Anne ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTICOSTERONE; DEHYDROCORTICOSTERONE; GLUCOCORTICOID;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; WEIGHT GAIN;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSITY; ANIMALS; BIOLOGICAL MARKERS; CORTICOSTERONE; DOWN-REGULATION; GLUCOCORTICOIDS; HYPERINSULINISM; HYPERPHAGIA; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PITUITARY-ADRENAL SYSTEM; WEIGHT GAIN;

EID: 84884693007     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1362     Document Type: Article

References (40)

1. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692-2701.
2. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension. 1999;33:1364-1368. (Pubitemid 29282655)
3. Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol. 2010;122:21-27.
4. Shpilberg Y, Beaudry JL, D'Souza A, Campbell JE, Peckett A, Riddell MC. A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis Models Mech. 2012;5:671-680.
5. Waters P, McCormick CM. Caveats of chronic exogenous corticosterone treatments in adolescent rats and effects on anxiety-like and depressive behavior and hypothalamic-pituitary-adrenal (HPA) axis function. Biol Mood Anxiety Disord. 2011;1:4.
6. Pung T, Zimmerman K, Klein B, Ehrich M. Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. Toxicol Ind Health. 2003;19:171-182. (Pubitemid 40193715)
7. Marchington D, Rothwell NJ, Stock MJ, York DA. Energy balance, diet-induced thermogenesis and brown adipose tissue in lean and obese (fa/fa) Zucker rats after adrenalectomy. J Nutr. 1983;113:1395-1402.
8. Makimura H, Mizuno TM, Roberts J, Silverstein J, Beasley J, Mobbs CV. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes. 2000;49:1917-1923.
9. Coll AP, Fassnacht M, Klammer S, et al. Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1-28 to Pomc-/- mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. J Endocrinol. 2006;190:515-525. (Pubitemid 44288387)
10. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McEwen BS. Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology. 2010;151:2117-2127.
11. Harno E, White A. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? Trends Endocrinol Metab. 2010;21:619-627.
12. Cooper MS, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab. 2009;94:4645-4654.
13. Hughes KA, Webster SP, Walker BR. 11-β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Invest Drugs. 2008;17:481-496. (Pubitemid 351578167)
14. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101:7088-7093. (Pubitemid 38596447)
15. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-2170. (Pubitemid 33150673)
16. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517-527. (Pubitemid 41186950)
17. Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE. 11β-Hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol. 1998;64:251-260. (Pubitemid 28221628)
18. Stovold R, Meredith SL, Bryant JL, et al. Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. Br J Cancer. 2013;108(8):1704-1711.
19. Carter RN, Paterson JM, Tworowska U, et al. Hypothalamic-pituitary- adrenal axis abnormalities in response to deletion of 11β-HSD1 is strain-dependent. J Neuroendocrinol. 2009;21:879-887.
20. Tagawa N, Ikariko N, Fukumura K, Kobayashi Y. Development of an enzyme-linked immunosorbent assay for serum 11-dehydrocorticosterone in rat and mouse. Biol Pharmaceut Bull. 2007;30:403-409. (Pubitemid 46355911)
21. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary- adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology. 2001;142:114-120. (Pubitemid 32183672)
22. Brunton PJ, Sausbier M, Wietzorrek G, et al. Hypothalamic-pituitary- adrenal axis hyporesponsiveness to restraint stress in mice deficient for large-conductance calcium- and voltage-activated potassium (BK) channels. Endocrinology. 2007;148:5496-5506. (Pubitemid 350012621)
23. Lavery GG, Zielinska AE, Gathercole LL, et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2012;153:3236-3248.
24. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931-938. (Pubitemid 38436604)
25. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94:14924-14929. (Pubitemid 28041476)
26. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60:1500-1510.
27. Hassan-Smith Z, Morgan SA, Bujalska IJ, et al. 11β-HSD1KO mice are protected from glucocorticoid dependent age-associated muscle atrophy. Endocr Abstr. 2013;31:OC1.3.
28. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin Sci (Lond). 2001;101:739-747. (Pubitemid 33135358)
29. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615-622. (Pubitemid 43326866)
30. Like AA, Chick WL. Pancreatic β cell replication induced by glucocorticoids in subhuman primates. Am J Pathol. 1974;75:329-348.
31. Rafacho A, Abrantes JL, Ribeiro DL, et al. Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Hormone Metab Res. 2011;43:275-281.
32. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122:4172-4189.
33. Morgan SA, Sherlock M, Gathercole LL, et al. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. 2009;58:2506-2515.
34. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes. 2009;58:46-53.
35. Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC, Walker BR. Increased whole-body and sustained liver cortisol regeneration by 11β-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes. 2011;60:720-725.
36. Densmore VS, Morton NM, Mullins JJ, Seckl JR. 11β-Hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: a novel constraint to hyperphagia? Endocrinology. 2006;147:4486-4495. (Pubitemid 44268400)
37. Yau JL, McNair KM, Noble J, et al. Enhanced hippocampal long-term potentiation and spatial learning in aged 11β-hydroxysteroid dehydrogenase type 1 knock-out mice. J Neurosci. 2007;27:10487-10496. (Pubitemid 47502008)
38. Yau JL, Noble J, Seckl JR. 11β-Hydroxysteroid dehydrogenase type 1 deficiency prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control. J Neurosci. 2011;31:4188-4193.
39. Wamil M, Battle JH, Turban S, et al. Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β- hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2011;60:1158-1167.
40. Yau JL, Noble J, Kenyon CJ, et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA. 2001;98:4716-4721. (Pubitemid 32295042)